Mon Dec 13, 2010 16:39 GMT |
BMI believes the commercial success of the pharmaceutical industry depends on innovation to a much greater extent than any other industry. The long-term success of the sector is highly dependent on maintaining a steady rate of new product launches, to replace older products with expired patents and recover revenues lost to the generic drug sector…. [Read more]
Tags: biotechnology, business model, cures, drug discovery, drugs, industry, innovation, medicines, patents, Pharmaceuticals, R&D, Regulation, research and development, venture capital
Posted in: Africa, Asia, China, FDI, General, Latin America, US
Mon May 17, 2010 15:57 GMT |
The European private equity industry looks to be fighting a losing battle against regulators. The introduction of a new regulatory framework, that will most likely undermine the recovery in PE activity just as it has started to gather traction, is set to go to a vote in the European Parliament this week. While my colleagues… [Read more]
Tags: alternative investment, EU, European Union, funding, Hedge Funds, private equity, Regulation
Posted in: Eurozone, Financials, General, Political Risk, UK